Objective: The aim of this study was to identify provider characteristics associated with hormone therapy prescribing. Methods: The study design is cross-sectional. In December 2005, we mailed surveys to providers practicing in two integrated healthcare delivery systems located in the northwestern and northeastern United States; 379 responded (74%) and 249 (49% of total) granted access to their automated data. Data included provider demographics, practice characteristics, and perceptions about hormone therapy. Provider-specific annual hormone therapy prescribing frequency was calculated as days supply of hormone therapy filled divided by the number of visits (among women aged 45-80 y). Factors associated with higher rates of hormone therapy prescribing were identified using bivariate and multivariate analyses.
Since the release of the WHI findings, providers seem to be more conservative in their prescribing of HT. HT use has plummeted, 8 and spending for promotional activities by pharmaceutical industry has declined. 9 Nevertheless, a recent survey of American College of Obstetrics and Gynecology fellows reports that 49% of respondents did not find the WHI results convincing. 10 Providers are the integral connection between research and its translation to clinical practice, and their advice is an important factor in women's decision to use HT. 11<15 In this complex arena of clinical practice, physicians' knowledge, views, education, and experience may influence their decision to prescribe HT.
Since the release of the WHI findings, there have been studies reporting prescribing practices in the United States and factors associated with these practices. 16<18 However, to our knowledge, no studies include both self-reported provider information and an objective measure of HT prescribing. In this study, we assess the associations between an objective measure of HT prescribing frequency constructed from automated pharmacy and clinic visit data and provider characteristics including (1) demographics, (2) practice type, (3) scientific knowledge and views, (4) perception of patient views regarding HT use, and (5) self-rated HT prescribing practice.
METHODS Setting
The study was conducted at two locations: (1) a northwest site (NW, Group Health), an integrated healthcare system in Washington State with more than 550,000 enrollees, including greater than 110,000 women aged 45 to 80 years, and (2) a northeast site (NE, Harvard-Vanguard Medical Associates), a multisite, multispecialty medical practice in the Greater Boston area, with more than 300,000 members.
Both locations released post-WHI guidelines, consistent with the American College of Obstetricians and Gynecologists recommendations. 19 At both locations, most patients are insured by plans with drug benefits. Both sites use a pharmaceutical formulary.
A self-administered survey, along with a $25 incentive, was mailed between December 2005 and March 2006, to all family practice physicians, internists, obstetrician/gynecologists (OB/GYNs), nurse practitioners, physician's assistants, and nurse midwives. Eligibility criteria included the following: (1) currently working at the healthcare organization, (2) worked at the healthcare organization for at least 12 months, (3) had 50 or more visits by women aged 45 to 80 years in the previous year, and (4) provided HT counseling and/or prescribed HT in the previous year. Providers who did not respond within 2 weeks received two successive reminder postcards and a third reminder with another copy of the survey. The institutional review boards at both sites approved the study.
Main outcome measure HT prescribing frequency
Our objective measure of HT prescribing frequency was calculated for providers who gave permission to view electronic pharmacy data. Using data for the 12-month period before the survey, we determined the total days supply of estrogen fills for women aged 45 to 80 years written by a particular provider. Ideally, our denominator would include the number of women reporting hot flashes seen by the provider during the year, but this information was not available. So instead, we used a definition similar to what has been used in previous work. 20 We divided the annual days supply of estrogen written by a provider by the total number of visits made to the provider during the year by women aged 45 to 80 years, the age when women are most likely to have vasomotor symptoms. At the NW site, this information was available for providers who worked at the staff model facilities. At the NE site, this information was available for the patients insured by Harvard Pilgrim Health Care, a health maintenance organization, which provided the researcher team with utilization data. NE providers also saw other patients who were insured by other healthcare plans. Therefore, both the average number of visits per provider and the average number of HT fills per provider were lower at the NE site as compared with the NW site (486 vs. 802 visits and 23 vs 122 fills, respectively). Days supply of HT was not directly available at the NE site. We created linear regression models based on NW information to convert NE data (drug name, form, strength, and quantity) to days supply.
Main exposure measures Provider characteristics
We obtained information on provider characteristics including age and sex and type of practice (physicians, nurse practitioners, nurse midwives, nursing other, physician's assistants). For analysis, field of practice was categorized as OB/GYN or primary care (PCP) (family practice or internal medicine).
To assess providers' perceptions of their patients' views regarding HT, they were asked to rate how relevant the WHI results are for perimenopausal women in their practice (irrelevant [1] to highly relevant [7] ) and how much they agree (strongly agree [1] to strongly disagree [5] [4] ) and to describe their knowledge about the Heart and Estrogen/ Progestin Replacement Study (HERS) and WHI trials (limited [1] to expert level [7] ).
Providers' views regarding the WHI findings were assessed by asking them if Bthe risks of estrogen with progestogen have been[ exaggerated (1) to appropriately described (7) . They also rated their agreement (strongly agree [1] to strongly disagree [5] ) that a convincing scientific case has been made for each of the risks and benefits of HT use including increased risk of breast cancer and stroke, the addition of progestogen to estrogen to prevent endometrial cancer, HT for the prevention of colon cancer, Alzheimer disease, osteoporosis, and coronary heart disease in women with or without diabetes.
Providers were also asked to categorize their rate of prescribing HT for menopausal women as compared with colleagues nationwide (very high [1] to very low [5] ); if, as a result of the WHI results, they are less likely to recommend HT for menopause symptoms (strongly agree [1] to strongly disagree [5] ); and to rate their emphasis on discontinuation of HT (encourage all women to discontinue as soon as possible [1] or let women using HT to continue as long as they want to [5] ).
Other covariates that could influence HT prescribing
To control for overall health of the women seen by a provider, we used the RxRisk score, a measure of health status based on an individual's age, sex, insurance status, and chronic condition profile measured by outpatient pharmacy dispenses. 21 This measure was only available for NW women and was averaged across all visits made by women aged 45 to 80 years, seen by the provider during the year before the survey.
We also computed the average age of women included in the denominator of a given provider's prescribing measure.
Analysis
We compared the characteristics of providers who did and did not provide permission to use automated data using Pearson's W 2 or Fisher's exact tests for percentages and F tests for means.
Associations between provider factors and prescribing frequency were first accessed in bivariate analyses using t tests for factors with two levels or one-way analysis of variance models for factors with three or more levels. For ordinal categorical variables, we used a linear regression model F statistic to test for trend. To determine which factors were most strongly associated with HT prescribing, we performed multivariable linear regression analysis that included provider factors that were associated with HT prescribing at an > e 0.1 significance level in the bivariate analysis. We fit the usual least-squares regression models to get the standard leastsquares P value and confidence intervals. We also computed empirical (sandwich) standard errors and P values to account for any nonnormality and heteroskedasticity (nonconstant variances) in our outcome of HT prescribing frequency. Because the least-squares and empirical standard errors and P values were similar, we present only the former. Because of the high correlation between years at the healthcare organization, provider age (correlation coefficient, 0.68), and years practicing medicine (correlation coefficient, 0.71), only one of these variables, years at the healthcare organization, was retained in the multivariable model. A Wald test was used to test interaction terms for site (NE or NW) and field of practice. Using a Bonferroni correction (0.05/number of interactions tested), an interaction was considered significant at an > e 0.003. 22 Because a number of significant interactions with field of practice were identified, separate multivariable models were performed for PCP and OB/GYN.
RESULTS
Of the 509 eligible providers, 379 providers (74%) completed the survey, and of these 249 (66%, 49% of total) consented to use of their automated prescription and visit data (NW n = 177; NE n = 72). Most respondents were physicians practicing at a healthcare organization for 10 or more years (Table 1) . Fifty-seven percent were females, of these 50% HT prescribing frequency: for the 12-month period before the survey, we divided the total days supply of estrogen fills for women aged 45 to 80 years, written by a particular provider, by the total number of visits made by women in the same age group to the provider. HT prescribing frequency: For the 12-month period before the survey, we divided the total days supply of estrogen fills for women aged 45 to 80 years written by a particular provider by the total number of visits made by women in the same age group to the provider. were premenopausal, and 32% of the perimenopausal or postmenopausal providers were using HT. Most PCPs at the NE site practiced in the field of internal medicine; most at the NW site were in family practice. There were no differences in sex (female in consenters, 57%; nonconsenters, 53%), field of practice (OB/GYN in consenters, 18%; nonconsenters, 16%), full-or part-time FTE (part-time FTE in consenters, 53%; nonconsenters, 50%), age (mean age of consenters, 49 y; nonconsenters, 50 y), or years practicing medicine (mean years in consenters, 20 y; nonconsenters, 19 y) between providers who did and did not give permission to access their automated data. Compared with colleagues nationwide, 78% of providers who self-rated their HT prescribing practices as high consented to use of their automated data versus 56% of those who self-rated their HT prescribing practices as low.
More than 50% of the providers believed that they had expert knowledge regarding the HERS and WHI trials, and 77% thought that the findings of the WHI trial were relevant to the women in their practice. There was excellent agreement between the objective measure of HT prescribing frequency based on automated data and the providers' self-described prescribing practices (Table 2) . Also, as expected, lower prescribing frequency was observed in providers whose average female patient was greater than 56 years of age (8.2 vs 18.0; P G 0.001) and whose patients had a higher degree of comorbidity (RxRisk: 9.3 upper tertile vs 13.0 lower tertile; P = 0.02) ( Table 3) .
HT prescribing frequency was greater for OB/GYNs than for PCPs and in the NW compared with the NE (NW PCPs: 9.4; NW OB/GYNs, 24.8; NE PCPs, 2.0, NE OB/GYNs, 8.5; P G 0.001). Other provider characteristics associated with higher HT prescribing in bivariate analysis included more years at the healthcare organization (P = 0.001), older provider age (P = 0.04), and a female provider using (P = 0.001) or likely to use HT herself (P = 0.02) ( Table 3) .
Providers' perceptions about patient preferences regarding HT use were also associated with HT prescribing in bivariate analysis. Mean HT prescribing frequency was lower among providers who thought that the WHI findings were relevant to perimenopausal women in their practice (9.0 vs 12.5 irrelevant to neutral; P = 0.03) and agreed that most women taking HT want to discontinue (8.4 vs disagree 12.8; P = 0.001).
On a population level, providers' perception about the strength of the scientific case for the preventive benefits and risks of HT use was not associated with HT prescribing frequency. However, HT prescribing frequency was higher for providers who felt that the risk of estrogen with progestogen had been exaggerated (14.5) compared with those who thought the risk had been appropriately described (8.3; P G 0.001). Providers' confidence in their knowledge also seemed important. Mean HT prescribing frequency was higher among providers who felt very well prepared to counsel women about HT (14.9 vs 8.7 somewhat or adequately prepared; P e 0.001) and reported expert knowledge of the recent trials (12.0 vs 6.4 limited or average; P e 0.001).
In multivariate linear regression that included variables associated with HT prescribing in bivariate analysis, the variables that were associated with HT prescribing were dependent on a provider's field of practice, so we ran these analyses separately for PC and OB/GYN providers. A statistically significant association remained, for both PCPs and OB/GYNs, between increased HT prescribing and practicing at the NW site and increased years at the healthcare organization (Table 4 ). Other characteristics associated with HT prescribing frequency a P values from linear regression model with provider prescribing frequency as the outcome and all variables listed in models as independent variables. All variables with P G 0.1 in the bivariate analyses were included in the multivariate models. Number of providers included in the regression analyses: 173 for model 1 (PCP) and 42 for model 2 (OB/GYN). Regression coefficients reflect mean difference in number of HT prescription days/visit for unit change in provider characteristic after controlling for other variables. varied depending on field of practice. PCPs who reported expert knowledge of the HERS and WHI trials, on average, prescribed 1 more day of HT per visit (P G 0.001) than providers with more limited knowledge. For OB/GYNs, feeling very well prepared to counsel women on HT use was associated with an average 10-day increase in HT prescribing per visit compared with providers who felt adequately or not at all prepared (P = 0.01). In addition, lower HT prescribing was associated with increasing age of their patient population (1.7-d less/visit for each increase in year of average patient age; P = 0.03) and with a provider's perception that the risks of estrogen with progestogen had been appropriately described in the WHI studies (2-d less/visit; P = 0.04) compared with providers who believed that it had been exaggerated.
DISCUSSION
This survey was conducted after early discontinuation and publication of the WHI estrogen 7 and estrogen plus progestin 5 trials and the WHI Memory Study. 6, 23 Surveyed providers practiced at healthcare organizations that provided guidelines consistent with prescribing HT for the relief or vasomotor symptoms at the lowest dose and for the shortest period, given a favorable risk-benefit analysis but not for prevention.
We observed lower HT prescribing frequency in the NE compared with the NW. This is consistent with findings reported by Hing and Brett. 16 Using data from the 2001-2003 National Ambulatory and National Hospital Ambulatory Medical Care Surveys, they reported that a lower percentage of visits by women 40 years or older living in the NE had HT referenced, as compared with other regions in the United States. Others have reported HT use to be less common for women in the NE. 24<26 In our study, most PCPs in our NW group were in family practice and those in the NE were internists. This makes it difficult to separate the effects of geography and field of practice in this group of providers. The lower prescribing frequency in the NE PCPs could be due to the higher percentage of internists in this sample. An earlier study (2003) of US physicians (633 OB/GYNs, 571 family practitioners, 410 internists) reported that internists were least likely to think that postmenopausal women should use HT. 18 However, this would not explain the lower HT prescribing in the NE that we observed in our OB/GYN group. Another possible explanation for the observed difference could be the methods we used to calculate the prescribing frequency at each site if our conversions of NE drug information (form, strength, and quantity) consistently underestimated days supply.
We observed higher HT prescribing by OB/GYNs compared with PCPs in bivariate analysis, and this difference was virtually the same in an ad hoc analysis that adjusted for provider age, sex, practice location, and average age of women making visits. Using our measure of HT prescribing frequency, it is conceivable that our denominator could contribute to this difference. It is possible that OB/GYNs in general only see patients once or twice a year but write HT prescriptions for the entire year, whereas PCPs may see patients for multiple conditions throughout the year, creating a higher HT prescribing measure for OB/GYNs. In our multivariable analyses, we controlled for this possibility by stratifying on field of practice. Furthermore, other post-WHI studies support our findings. Hing and Brett 16 noted that visits to gynecologists had a higher probability of resulting in HT prescription compared with visits to PCPs. In addition, in the 2003 survey noted above, compared with family practice and internal medicine physicians, a higher percentage of gynecologists reported that they strongly agreed that HT should be offered to postmenopausal women, were more supportive of longer durations of HT, and were more likely to note that combined HT reduces the risk of colon cancer. 18 Similar findings were reported from another survey sent to all PCPs in Florida in March of 2004 (10% response rate; 203 OB/ GYN, 145 internal medicine, 219 family practice). 27 A few explanations have been offered for this difference. Higher HT use has been reported in women with hysterectomies, 15 and it may be more likely that hysterectomized women or women experiencing menopausal symptoms see gynecologists, 20 or gynecologists may ask about menopause symptoms more often. Another suggestion is that internists may more often treat the negative outcomes associated with HT use. 18 Alternately, OB/GYNs could receive training that is more focused in women's health and feel more confident in prescribing HT. 18 This concept seems to be supported in our sample in that 35% of our OB/GYNs and 15% of our PCPs felt very well prepared to counsel women on HT and that 85% and 57%, respectively, felt that they had expert knowledge of the HERS and WHI trials.
In our study, greater provider confidence in the findings of the HT trials was independently related to higher HT prescribing for both OB/GYNs and PCPs. For OB/GYNs, this equated to how well prepared they were to counsel patients about HT; for PCPs, it was their knowledge of the trials. This is consistent with the findings from a 2003 American College of Obstetricians and Gynecologists survey of 703 fellows reporting that providers with comprehensive knowledge of the WHI trials found the trial evidence less convincing. 28 We also observed that the longer the OB/GYN or PCP had practiced at a specific healthcare organization, the greater the HT prescribing frequency independent of their knowledge of the trials, their preparedness to counsel on HT, and their opinion on whether the risks of estrogen and progestogen had been exaggerate. Interestingly, in a report on family medicine physicians in Florida, faculty members as compared with residents were more likely to use HT for treatment of menopausal symptoms. 17 Providers may carry forward practices learned while in training, and it is possible that older providers were trained in an era of more positive beliefs about the benefits of HT.
Our study has several strengths. To our knowledge, it is one of a few studies that assess the characteristics of US providers associated with HT prescribing after the release of the WHI findings, and we used an objective, data-based measure of HT prescribing frequency. Our study also has several limitations. A total of 49% of providers both completed the survey and consented to the use of their automated prescription. Differential response could introduce a response bias in the study. We had limited data available to compare responders and nonresponders; however, at the NW location, both groups were similar in age, 50 and 49 years, respectively. In addition, there was a similar proportion of nonresponse for PC (18%) and OB/GYN (16%) providers (P = 0.6). However, of the respondents, more providers who self-rated their prescribing practices as high compared with their colleagues nationally gave permission to use their automated data than those who rated their selves as low. Therefore, our findings may be more reflective of practitioners with a more favorable attitude toward HT. Our findings are also more reflective of providers who mostly serve the insured population. We only had information on patient comorbidity at the NW location, so it was not included in our multivariate analysis. However, comorbidity was highly correlated with patient age (correlation coefficient, 0.69), which was included in the model and could partially account for comorbidity in the population. Nor could we fully account for other characteristics of the patient population. In addition, our analysis does not address changes in dose or formulation of medication use, only days supply of medication.
CONCLUSIONS
Despite the downward trend in HT prescribing after the release of the WHI trial findings and in the context of similar practice guidelines, variation in prescribing practices associated with provider characteristics persists. The fact that HT prescribing was driven by years at the organization (a possible surrogate for age), region, self-rated trial knowledge, and feeling prepared to counsel suggests that HT prescribing may be driven by factors outside evidence-based medicine. If this is true, practice variability could result in unequal exposure to HT's risk and benefits. This affects a very large proportion of US women who, when inquiring about HT risk and benefits, deserve unbiased and well-informed counseling to make informed decisions. It is likely that some doctors need additional training to ensure this level of advice.
